<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1517</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Приверженность терапии и фиксированные комбинации при лечении артериальной гипертензии. Фокус на фиксированную комбинацию фелодипина и метопролола</article-title><trans-title-group xml:lang="en"><trans-title>Therapy compliance and fixed-dose combinations in arterial hypertension treatment. Focus on a fixed-dose combination of felodipine and metoprolol</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шальнова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalnova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заместитель директора по науке, руководитель отдела эпидемиологии неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">SShalnova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кукушкин</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Kukushkin</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ведущий научный сотрудник отдела эпидемиологии неинфекционных заболеваний.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маношкина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Manoshkina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Старший лаборант с высшим образованием кафедры госпитальной терапии №2 леч. факультетата МГМСУ.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГУ Государственный научно-исследовательский центр профилактической медицины Росмедтехнологии</institution></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2009</year></pub-date><volume>8</volume><issue>6</issue><fpage>77</fpage><lpage>81</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шальнова С.А., Кукушкин С.К., Маношкина Е.М., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Шальнова С.А., Кукушкин С.К., Маношкина Е.М.</copyright-holder><copyright-holder xml:lang="en">Shalnova S.A., Kukushkin S.K., Manoshkina E.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1517">https://cardiovascular.elpub.ru/jour/article/view/1517</self-uri><abstract><p>Статья посвящена весьма актуальному в настоящее время вопросу — применению фиксированных комбинаций лекарственных препаратов для лечения артериальной гипертонии (АГ), как одному из успешных методов повышения приверженности больных АГ лечению.</p></abstract><trans-abstract xml:lang="en"><p>The paper discusses fixed-dose combined therapy of arterial hypertension (AH), as an effective method for increasing AH treatment compliance.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>лечение</kwd><kwd>фиксированные комбинации препаратов</kwd><kwd>приверженность терапии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>treatment</kwd><kwd>fixed-dose combination</kwd><kwd>therapy compliance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines Subcommittee of the WHO-ISH. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.</mixed-citation><mixed-citation xml:lang="en">Guidelines Subcommittee of the WHO-ISH. 1999 World Health Organization — International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413-46.</mixed-citation><mixed-citation xml:lang="en">Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413-46.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105-87.</mixed-citation><mixed-citation xml:lang="en">2007 Guidelines for the management of Arterial hypertension. J Hypertens 2007; 25: 1105-87.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Национальные клинические рекомендации. Диагностика и лечение артериальной гипертензии. М.: “Силицея-Полиграф” 2008.</mixed-citation><mixed-citation xml:lang="en">Национальные клинические рекомендации. Диагностика и лечение артериальной гипертензии. М.: “Силицея-Полиграф” 2008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345-51.</mixed-citation><mixed-citation xml:lang="en">Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345-51.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Claxon AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.</mixed-citation><mixed-citation xml:lang="en">Claxon AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Domino FJ. Improving adherence to treatment of hypertension. Am Fam Physician 2005; 71: 2089-90.</mixed-citation><mixed-citation xml:lang="en">Domino FJ. Improving adherence to treatment of hypertension. Am Fam Physician 2005; 71: 2089-90.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Schroeder K, Fahey TK, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized control trails. Arch Intern Med 2004; 164: 722-32.</mixed-citation><mixed-citation xml:lang="en">Schroeder K, Fahey TK, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized control trails. Arch Intern Med 2004; 164: 722-32.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mitka M. Research probes details of poor adherence in antihypertension drug therapy JAMA 2007; 298: 2128.</mixed-citation><mixed-citation xml:lang="en">Mitka M. Research probes details of poor adherence in antihypertension drug therapy JAMA 2007; 298: 2128.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman R, Zou G, Vavdervoort, et al. A simplified approach to the treatment of uncomplicated hypertension/ A cluster randomized, controlled trail. Hypertens 2009; 53: 646-53.</mixed-citation><mixed-citation xml:lang="en">Feldman R, Zou G, Vavdervoort, et al. A simplified approach to the treatment of uncomplicated hypertension/ A cluster randomized, controlled trail. Hypertens 2009; 53: 646-53.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Neutel JB. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24: 2389-401.</mixed-citation><mixed-citation xml:lang="en">Neutel JB. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008; 24: 2389-401.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Kamalallannan G, Parkar S, Messerli FH. Fixed- dose combinations improve medication adherence: a metaanalysis. Am J Med 2008; 120: 713-9.</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Kamalallannan G, Parkar S, Messerli FH. Fixed- dose combinations improve medication adherence: a metaanalysis. Am J Med 2008; 120: 713-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.</mixed-citation><mixed-citation xml:lang="en">Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259(13): 1976-82.</mixed-citation><mixed-citation xml:lang="en">Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259(13): 1976-82.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">MERIT-HF Study Group. Effect ofmetoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.</mixed-citation><mixed-citation xml:lang="en">MERIT-HF Study Group. Effect ofmetoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hedblad В, Wikslrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness (IMT): main results from the Beta-blocker Cholester ol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.</mixed-citation><mixed-citation xml:lang="en">Hedblad В, Wikslrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness (IMT): main results from the Beta-blocker Cholester ol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wiklund O, Hulthe J, Wlkstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year ran¬domized study. Stroke 2002; 33: 572-7.</mixed-citation><mixed-citation xml:lang="en">Wiklund O, Hulthe J, Wlkstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year ran¬domized study. Stroke 2002; 33: 572-7.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L, Zanchetti A, for the HOT study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. Blood Press 1997; 6: 313-7.</mixed-citation><mixed-citation xml:lang="en">Hansson L, Zanchetti A, for the HOT study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. Blood Press 1997; 6: 313-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with. Circulation 1997; 96: 856-63 enalapril. V-Heft III</mixed-citation><mixed-citation xml:lang="en">Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with. Circulation 1997; 96: 856-63 enalapril. V-Heft III</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.</mixed-citation><mixed-citation xml:lang="en">Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. Blood Press 1993; 2 Suppl. 1: 22-9.</mixed-citation><mixed-citation xml:lang="en">Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. Blood Press 1993; 2 Suppl. 1: 22-9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Trenkwalder P, Elmfeldt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs — the rationale and benefits of combining felodipine and metoprolol. J Hum Hypertens 1995; 9 Suppl. 2: 37-42.</mixed-citation><mixed-citation xml:lang="en">Trenkwalder P, Elmfeldt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs — the rationale and benefits of combining felodipine and metoprolol. J Hum Hypertens 1995; 9 Suppl. 2: 37-42.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Siewert-Delle A, Ljungman S, Hartford M. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension: addition of felodipine or ramipril to long-term treatment with beta-blockade. Am J Hypertens 1995; 8: 113-23.</mixed-citation><mixed-citation xml:lang="en">Siewert-Delle A, Ljungman S, Hartford M. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension: addition of felodipine or ramipril to long-term treatment with beta-blockade. Am J Hypertens 1995; 8: 113-23.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof В, Pennert К, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.</mixed-citation><mixed-citation xml:lang="en">Dahlof В, Pennert К, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Freeling P, Davis RH, Goves JR, et al. Control of hypertension in elderly patients with felodipine and metoprolol: a double blind, placebo-controlled clinical trial. Br J Clin Pharmacol 1987; 24: 459-64.</mixed-citation><mixed-citation xml:lang="en">Freeling P, Davis RH, Goves JR, et al. Control of hypertension in elderly patients with felodipine and metoprolol: a double blind, placebo-controlled clinical trial. Br J Clin Pharmacol 1987; 24: 459-64.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jennings GL, Sudhir K, Laufer E. Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. J Hum Hypertens 1995; 9: 181-6.</mixed-citation><mixed-citation xml:lang="en">Jennings GL, Sudhir K, Laufer E. Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. J Hum Hypertens 1995; 9: 181-6.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Missault LH, Friart A, Van BP. Efficacy, tolerability and quality of life in the Hypertension Optimal Reduction by Treatment Adjustments — trial (abstract). Cardiovasc Drugs Ther 1999; 13:68.</mixed-citation><mixed-citation xml:lang="en">Missault LH, Friart A, Van BP. Efficacy, tolerability and quality of life in the Hypertension Optimal Reduction by Treatment Adjustments — trial (abstract). Cardiovasc Drugs Ther 1999; 13:68.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, Jonsson L, Borgholst 0, et al. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Press 1993; 2 Suppl. 1: 37-45.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, Jonsson L, Borgholst 0, et al. Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. Blood Press 1993; 2 Suppl. 1: 37-45.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a fixed combination of metoprolol and felodipine in comparison with the individual substances in monotherapy. J Car diovasc Pharmacol 1990; 16: 910-6.</mixed-citation><mixed-citation xml:lang="en">Dahlof В, Hosie J. Antihypertensive efficacy and tolerability of a fixed combination of metoprolol and felodipine in comparison with the individual substances in monotherapy. J Car diovasc Pharmacol 1990; 16: 910-6.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Klein G, German MC, Study Group. Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. Blood Press 1998; 7: 308-12.</mixed-citation><mixed-citation xml:lang="en">Klein G, German MC, Study Group. Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. Blood Press 1998; 7: 308-12.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Berger A, Chima P, Dawes M, et al. A fixed combination of felodipine 5mg and metoprolol 50mg compared with double doses of the individual components as antihypertensive therapy. J Drug Dev 1992; 4: 199-206.</mixed-citation><mixed-citation xml:lang="en">Berger A, Chima P, Dawes M, et al. A fixed combination of felodipine 5mg and metoprolol 50mg compared with double doses of the individual components as antihypertensive therapy. J Drug Dev 1992; 4: 199-206.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hosie J, DahlofB, Klein G. The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. Blood Press 1993; 2 Suppl 1: 46-50.</mixed-citation><mixed-citation xml:lang="en">Hosie J, DahlofB, Klein G. The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. Blood Press 1993; 2 Suppl 1: 46-50.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44: 251-77.</mixed-citation><mixed-citation xml:lang="en">Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44: 251-77.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann J. Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. Blood Press 1993; 2 Suppl. 1: 30-6.</mixed-citation><mixed-citation xml:lang="en">Hoffmann J. Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. Blood Press 1993; 2 Suppl. 1: 30-6.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Clin Exp Hypertens 1998; 20: 833-46.</mixed-citation><mixed-citation xml:lang="en">Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Clin Exp Hypertens 1998; 20: 833-46.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Glasgow RE, Emmons KM. How we can increase translation of research into practice? Type of evidence needed. Ann Rev Publ Health 2007; 28: 413-33.</mixed-citation><mixed-citation xml:lang="en">Glasgow RE, Emmons KM. How we can increase translation of research into practice? Type of evidence needed. Ann Rev Publ Health 2007; 28: 413-33.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Frankle AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Making 2008; 8: 38 (1-11).</mixed-citation><mixed-citation xml:lang="en">Frankle AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Making 2008; 8: 38 (1-11).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
